ClinicalTrials.gg
RecruitingNCT07161479Updated Feb 6, 2026

Argon Plasma Coagulation Versus Endoscopic Mucosal Resection for Gastric Adenoma (CLER-GA)

An interventional study of Argon Plasma Coagulation (APC) and Endoscopic Mucosal Resection (EMR) in Gastric Adenoma, Stomach Neoplasms and Precancerous Conditions, sponsored by Samsung Medical Center. Recruiting at 3 sites in South Korea. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by Samsung Medical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Stomach Neoplasms by Samsung Medical Center — 6 open to participants now, 7 under way, none of them phase 3. Stomach Neoplasms · Samsung Medical Center.

Planned enrollment
10th of 32
160 · median 66
Started
2026
with 2 others
No phase
6 of 40
3 open now
Registered
37th of 40
by date

Among the 40 studies in Stomach Neoplasms by Samsung Medical Center, this one is the 10th largest by planned enrollment of the 32 interventional ones that give a count, is one of 3 that started in 2026, is one of 6 with no phase, and was the 37th registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

6 of the 40 studies in Stomach Neoplasms by Samsung Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Stomach Neoplasms by Samsung Medical Center, or all of them as a file.
02

Study summary

Gastric adenomas with low-grade dysplasia (LGD) are considered precancerous lesions of the stomach. While these lesions carry a lower risk of progressing to gastric cancer compared with high-grade dysplasia, there is still uncertainty about the best way to manage them. International medical guidelines differ in their recommendations, and for very small lesions (1 cm or smaller), some guidelines provide no clear direction. This creates uncertainty for both patients and physicians about whether to treat these lesions or simply observe them over time.

Two endoscopic treatment methods are widely used in clinical practice: endoscopic mucosal resection (EMR) and argon plasma coagulation (APC). EMR involves lifting and cutting out the lesion. Its major advantage is that it removes the lesion completely and allows for detailed pathological examination. However, EMR can be technically more demanding, takes more time, and may carry higher risks of complications such as bleeding or perforation. It also usually involves higher medical costs.

In contrast, APC is a technique that uses ionized argon gas and electrical current to coagulate tissue without direct contact. APC is simpler to perform, takes less time, and is generally less invasive. Patients undergoing APC may have shorter hospital stays, lower costs, and fewer complications. However, APC does not provide a specimen for pathology, so complete removal of the lesion cannot be confirmed. This means there is a possibility of local recurrence.

Several retrospective studies have examined APC for gastric LGD, and results have suggested it may be effective for small lesions. However, recurrence rates reported in previous studies have varied widely, from less than 2% to more than 20%. Importantly, no large randomized controlled trial has directly compared APC with EMR for small gastric LGD lesions. This study seeks to fill that gap.

The goal of this clinical trial is to compare the effectiveness and safety of APC and EMR for treating gastric adenomas that are 1 cm or smaller with low-grade dysplasia. Specifically, the study aims to determine whether APC is "non-inferior" to EMR in preventing local recurrence of these lesions. In other words, researchers want to know if APC works just as well as EMR in controlling the disease, while also offering potential advantages such as fewer complications, shorter procedure time, and lower costs.

Participants in this study will:

Be adults (age 20 or older) diagnosed with a gastric adenoma 1 cm or smaller with low-grade dysplasia.

Be randomly assigned (by chance, like flipping a coin) to receive either APC or EMR.

Receive standard medical care after the procedure, including medications to help the stomach heal.

Return for follow-up endoscopy at 3 months and 12 months after the procedure. During these visits, the treated area will be checked carefully, and biopsies may be taken to determine whether the lesion has recurred.

Provide information about any complications, the duration of the procedure, and their recovery experience.

The main question is whether APC can prevent recurrence of gastric adenomas as effectively as EMR. Secondary questions include how the two treatments differ in terms of complications (such as bleeding or perforation) and procedure time.

Both APC and EMR are already established and commonly used treatments for gastric lesions. By directly comparing these two methods in a randomized controlled trial, this study will provide important evidence to guide future recommendations for patients with small gastric adenomas. The findings may help physicians and patients choose the best treatment option, balancing safety, effectiveness, and convenience.

Read the detailed description

Gastric adenomas with low-grade dysplasia (LGD) represent precancerous changes in the stomach lining. Unlike high-grade dysplasia (HGD), which carries a well-established high risk of progression to gastric cancer and is uniformly recommended for endoscopic resection, LGD has a much lower risk of malignant transformation. Some long-term follow-up studies suggest that fewer than 10% of LGD lesions progress to cancer within five years. As a result, there has been longstanding debate over whether LGD lesions, particularly those measuring 1 cm or smaller, should be actively treated or only monitored.

International guidelines differ on this issue. The Vienna classification recommends either endoscopic resection or close surveillance. The American Society of Gastrointestinal Endoscopy (ASGE) guidelines do not provide explicit recommendations for LGD, focusing instead on HGD and cancer. The British Society of Gastroenterology (BSG) advises complete removal of adenomas but without specifying the method. Only the updated European Society of Gastrointestinal Endoscopy (ESGE) guideline explicitly recommends endoscopic mucosal resection (EMR) for lesions smaller than 1 cm, while larger or suspicious lesions should be treated with endoscopic submucosal dissection (ESD). In contrast, Japanese and Korean gastric cancer guidelines primarily address early gastric cancer and provide no guidance specific to adenomas.

Currently, EMR and ESD are considered standard resection techniques. EMR is suitable for small, superficial lesions and allows en bloc removal with pathological confirmation, but it involves technical demands, longer procedure time, higher risk of complications, and greater costs. ESD extends these advantages to larger or fibrotic lesions but is even more technically demanding. In comparison, argon plasma coagulation (APC) is a non-contact ablative method using ionized argon gas to deliver high-frequency current. APC has been widely applied in therapeutic endoscopy for hemostasis and tissue ablation. It is technically simple, quicker, less invasive, and associated with fewer complications and lower costs. However, APC does not yield a resection specimen, making it impossible to confirm complete removal histologically, and the possibility of local recurrence remains.

Several retrospective studies have evaluated APC for gastric LGD, reporting local recurrence rates ranging from 1.7% to over 20%. The largest cohort suggested a recurrence rate of 2.6% for lesions ≤1 cm, compared to higher recurrence for 1-2 cm lesions. These results suggest that APC may be suitable for selected small LGD lesions, but the lack of randomized controlled trials (RCTs) leaves considerable uncertainty. Importantly, no RCT has directly compared APC with EMR, the standard resection method, in this specific population.

This study is therefore designed as a multicenter, randomized, single-blinded, controlled trial to evaluate whether APC is non-inferior to EMR in preventing local recurrence of gastric adenomas with LGD measuring 1 cm or smaller. A total of 160 adult participants will be enrolled across multiple academic hospitals in Korea. Eligible patients will be randomized 1:1 to receive either APC or EMR. Standard post-procedure management will be provided to all patients, including fasting, acid suppression, and routine monitoring. Participants will be followed for at least 12 months, with surveillance endoscopies scheduled at 3 months and 12 months to assess the treated site and obtain biopsies when indicated.

The primary endpoint is local recurrence rate at 12 months, defined as histological confirmation of LGD at the treated site. Secondary endpoints include overall procedure outcomes (complete ablation or en bloc resection), procedure-related complications (bleeding, perforation), procedure time, and hospitalization outcomes. Statistical analysis will follow both intention-to-treat and per-protocol principles, with non-inferiority margins prespecified.

Both APC and EMR are already established in routine practice and are not investigational devices in the United States. This trial does not involve an FDA IND or IDE. The significance of this study lies in generating high-quality prospective evidence that can directly inform clinical decision-making for patients with gastric LGD. If APC proves to be non-inferior to EMR, it could provide a simpler, less invasive, and more cost-effective alternative for selected patients with small adenomas, reducing procedure time and complication risk while maintaining effectiveness in preventing recurrence. Conversely, if APC shows inferior outcomes, it would reinforce EMR as the standard of care.

This study addresses an important knowledge gap in the management of gastric LGD and has potential to influence future guideline recommendations worldwide.

03

Conditions studied

  • Gastric Adenoma
  • Stomach Neoplasms
  • Precancerous Conditions
  • Dysplasia Stomach

Keywords

  • Gastric adenoma
  • Low-grade dysplasia
  • Precancerous gastric lesion
  • Argon plasma coagulation (APC)
  • Endoscopic mucosal resection (EMR)
  • Endoscopic therapy
  • Local recurrence
  • Randomized controlled trial
  • Stomach neoplasms
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 20 years or older
  • Diagnosed with gastric adenoma with low-grade dysplasia measuring ≤ 1 cm on endoscopy
  • Scheduled to undergo endoscopic treatment
  • Able and willing to provide written

Exclusion criteria

Exclusion Criteria:

  • Previous treatment for gastric adenoma or gastric cancer
  • History of gastrectomy
  • Diagnosis of gastric cancer or high-grade dysplasia at the time of enrollment
  • Presence of multiple gastric adenomas
  • Pregnant, breastfeeding, or possibility of pregnancy
  • Uncontrolled chronic illnesses that may interfere with trial participation (e.g., uncontrolled hypertension, uncontrolled diabetes, chronic kidney disease, ascites, heart failure, psychiatric disorders)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Argon Plasma Coagulation (APC)

    Participants undergo argon plasma coagulation for gastric adenoma ≤ 1 cm.

    Procedure: Argon Plasma Coagulation (APC)

  • Active comparator
    Endoscopic Mucosal Resection (EMR)

    Participants undergo endoscopic mucosal resection for gastric adenoma ≤ 1 cm.

    Procedure: Endoscopic Mucosal Resection (EMR)

Interventions

  • ProcedureArgon Plasma Coagulation (APC)

    Ablation of gastric adenoma using argon plasma coagulation.

  • ProcedureEndoscopic Mucosal Resection (EMR)

    Endoscopic resection of gastric adenoma by mucosal resection technique.

06

What researchers measure

Primary outcomes

  1. Local recurrence rate of gastric adenoma with low-grade dysplasia

    Proportion of participants with histologically confirmed recurrence of gastric adenoma at the treated site, as determined by follow-up endoscopy and biopsy.

    Time frame: 12 months after treatment

Secondary outcomes

  1. Procedure outcomes

    Proportion of participants with complete ablation by APC or en bloc resection by EMR.

    Time frame: At the time of index procedure

  2. Procedure-related bleeding

    Proportion of participants with bleeding defined as a hemoglobin decrease \>2 g/dL accompanied by hematemesis, melena, or hypotension, occurring within 4 weeks of treatment.

    Time frame: Within 4 weeks after treatment

  3. Procedure-related perforation

    Proportion of participants with perforation, defined as direct endoscopic evidence during the procedure or free air detected on chest radiograph after the procedure. Subcategories include gross perforation and microscopic perforation.

    Time frame: Within 4 weeks after treatment

  4. Procedure time

    Average duration of the endoscopic procedure (APC or EMR), measured in minutes and seconds.

    Time frame: At the time of index procedure

07

Study locations

3 of 3 sites recruiting
08

References and documents

Publications

  • Kim IH, Kang SJ, Choi W, Seo AN, Eom BW, Kang B, Kim BJ, Min BH, Tae CH, Choi CI, Lee CK, An HJ, Byun HK, Im HS, Kim HD, Cho JH, Pak K, Kim JJ, Bae JS, Yu JI, Lee JW, Choi J, Kim JH, Choi M, Jung MR, Seo N, Eom SS, Ahn S, Kim SJ, Lee SH, Lim SH, Kim TH, Han HS; Development Working Group for the Korean Practice Guideline for Gastric Cancer 2024 Task Force Team. Korean Practice Guidelines for Gastric Cancer 2024: An Evidence-based, Multidisciplinary Approach (Update of 2022 Guideline). J Gastric Cancer. 2025 Jan;25(1):5-114. doi: 10.5230/jgc.2025.25.e11. PubMed 39822170 ↗
  • Pimentel-Nunes P, Libanio D, Bastiaansen BAJ, Bhandari P, Bisschops R, Bourke MJ, Esposito G, Lemmers A, Maselli R, Messmann H, Pech O, Pioche M, Vieth M, Weusten BLAM, van Hooft JE, Deprez PH, Dinis-Ribeiro M. Endoscopic submucosal dissection for superficial gastrointestinal lesions: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2022. Endoscopy. 2022 Jun;54(6):591-622. doi: 10.1055/a-1811-7025. Epub 2022 May 6. PubMed 35523224 ↗
  • Zhao G, Xue M, Hu Y, Lai S, Chen S, Wang L. How Commonly Is the Diagnosis of Gastric Low Grade Dysplasia Upgraded following Endoscopic Resection? A Meta-Analysis. PLoS One. 2015 Jul 16;10(7):e0132699. doi: 10.1371/journal.pone.0132699. eCollection 2015. PubMed 26182344 ↗
  • Cho SJ, Choi IJ, Kim CG, Lee JY, Kook MC, Park S, Ryu KW, Lee JH, Kim YW. Risk of high-grade dysplasia or carcinoma in gastric biopsy-proven low-grade dysplasia: an analysis using the Vienna classification. Endoscopy. 2011 Jun;43(6):465-71. doi: 10.1055/s-0030-1256236. Epub 2011 Mar 21. PubMed 21425043 ↗
  • Jung SJ, Cho SJ, Choi IJ, Kook MC, Kim CG, Lee JY, Park SR, Lee JH, Ryu KW, Kim YW. Argon plasma coagulation is safe and effective for treating smaller gastric lesions with low-grade dysplasia: a comparison with endoscopic submucosal dissection. Surg Endosc. 2013 Apr;27(4):1211-8. doi: 10.1007/s00464-012-2577-9. Epub 2012 Oct 18. PubMed 23076459 ↗

Individual participant data

Plan to share: Yes — De-identified data may be shared upon reasonable request

Supporting information: Study protocol, Statistical analysis plan

Time frame: De-identified individual participant data (IPD) and supporting documents will be made available beginning 6 months after publication of the main study results and will be accessible for up to 3 years thereafter.

Access criteria: De-identified individual participant data (IPD) and supporting information (study protocol, statistical analysis plan) will be made available to qualified researchers affiliated with academic or medical institutions. Interested researchers must submit a written proposal describing the intended use of the data. Access will be granted after review and approval by the principal investigator. A data use agreement must be signed prior to release. Data will be shared through a secure institutional platform or by direct request to the principal investigator.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Aug 2026, 7 months after the start.

Of 358 non-industry interventional studies with no phase under Stomach Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 63. This study's planned 7 months is below that.

Counting every sponsor, half of 369 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2025
First posted
Sep 8, 2025
StartActual
Jan 20, 2026
Primary completionEst.
Aug 2026
CompletionEst.
Oct 2026
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07161479
Responsible party
Hyuk Lee (Professor, Samsung Medical Center) — Principal investigator
First posted
Sep 8, 2025
Start date
Jan 20, 2026
Primary completion
Aug 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Feb 6, 2026

Study contacts

Clinical Research Coordinator
Contact
minjicho630@naver.com
82-2-3410-6853
Hyuk Lee, MD, PhD
principal investigator · Samsung Medical Center
Hyo-Joon Yang, MD, PhD
principal investigator · Kangbuk Samsung Hospital
Young-Il Kim, MD, PhD
principal investigator · National Cancer Center
Jong Yeul Lee, MD, PhD
principal investigator · National Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion